PDCD1 and neoplasm: Similarly, the combined anti-PD-1 antibody + chidamide treatment regimen showed synergistic activity, with primary tumor eradication in 1 out of 5 mice and 40% survival at day 42 after tumor implantation (SFig. 1D).